Abonnez-vous à la Base de données d’Antiviral InteliStrat

Vous devez être abonné pour avoir accès à la Base de données (Database). Plusieurs options d’abonnement avec des coûts dinscription variés sont disponibles tel que détaillé à la page Services.


L’échantillon ci-dessous montre le type d’information accessible à un abonné de la Base de données pour quelques produits typiques. Cela inclut aussi les Fiches détaillées des produits qui peuvent être visualisées en cliquant sur le nom des produits dans la grille.

Accéder à votre compte

Si vous avez déjà votre compte, veuillez vous authentifier.


Se connecter
Si vous n'avez pas de compte, veuillez vous inscrire.
S'inscrire
'

Échantillon de la database

  Promoteur(s) Produit Type de produit Mode d'action Famille virale Virus Statut-1 Statut-2 Order
Sanofi (Sanofi Pasteur / Sanofi Aventis / Sanofi Genzyme) (global presence)  Dengvaxia
Dengvaxia®; ChimeriVax-Dengue; ChimeriVax Dengue; CYD Dengue; CYD-TDV; CYD TDV
 
Vaccine  Vaccine based on Recombinant, viral expression vector  Flaviviridae  Dengue virus (DENV)  Market / Licensed for use  Approved for market in Mexico (Dec. 2015), Philippines (Dec. 2015), Brazil (Dec. 2015), Salvador (Jan. 2016), EU (Dec. 19, 2018), USA (May 2019); Filings for marketing authorization completed in several countries endemic for Dengue Fever virus; See Rema 
Argos Therapeutics (formerly Merix Bioscience; USA)  AGS-004
AGS004; AGS 004; Arcelis
 
Vaccine  Other  Retroviridae  HIV (Human Immunodeficiency virus)  Phase II  2 Phase II trials completed (2011 and 2015) 
GSK (GlaxoSmithKline; Glaxo Wellcome) (global presence)  Retrovir®
Zidovudine; Azidothymidine; AZT; BW A509U; Zydowin
 
Inhibitor  Nucleoside/Nucleotide RT Inhibitor (including NRTI, NRTTI and NcRTI Inhibitors)  Retroviridae  HIV (Human Immunodeficiency virus)  Market / Licensed for use  Approved for market in US (Mar. 19, 1987) and other markets 
Pharmacor (acquired by Procyon/Ambrilia Biopharma; Canada) (no longer in operation)  P-1946
P1946; P 1946
 
Inhibitor  Protease Inhibitor (PI)  Retroviridae  HIV (Human Immunodeficiency virus)  Preclinical  Lead compound 
TaiMed Biologics (Taiwan, USA)  Trogarzo™
Ibalizumab; Ibalizumab-uiyk; TNX-355; TNX355; TNX 355; Hu5A8; TMB-355; TMB355; TMB 355
 
Antibodies  Entry and/or Fusion inhibitor (single agent)  Retroviridae  HIV (Human Immunodeficiency virus)  Market / Licensed for use  Orphan Drug status; Fast track status; Breakthrough Therapy Designation (Feb. 2015); Priority Review status granted by FDA (Jun. 2017), and FDA approval for US market granted on Mar. 06, 2018; Approved for EU market (Sep. 26, 2019); See Remarks 
Novartis (global) / Novartis Institutes for BioMedical Research (NIBR) / Novartis Institute for Tropical Diseases (NITD)  Focetria®
Focetria® A(H1N1); Focetria A(H1N1); Focetria A/H1N1; Influenza A (H1N1) 2009 Monovalent Vaccine
 
Vaccine  Non-recombinant protein (subunit) vaccine  Orthomyxoviridae  Swine Influenza virus  Market / Licensed for use  Approved by EMEA for distribution in EU (Sept. 29, 2009) under control of health authorities and governments; WHO-Prequalification status; No longer available (2015); See Remarks 
Abbott / AbbVie (global presence)  A-837093
A-837,093; A837093; A 837093
 
Inhibitor  RNA Polymerase Inhibitor  Flaviviridae  HCV (Hepatitis C virus)  Preclinical  No further development 
Abbott / AbbVie (global presence)  Paritaprevir
Veruprevir; ABT-450; ABT450; ABT 450
 
Inhibitor  Protease Inhibitor (PI)  Flaviviridae  HCV (Hepatitis C virus)  Market / Licensed for use  Approved for market in US (Dec. 2014)and other markets as part of combination therapy called Viekira Pak; See Remarks 
Novavax (USA) (formerly DynCorp)  ResVax™
RSV-F VLP vaccine; RSV vaccine; RSV F-VLP vaccine; RSV F VLP vaccine; RSV F vaccine
 
Vaccine  Recombinant protein (subunit) or nanoparticle/VLP vaccine  Pneumoviridae  RSV (Respiratory Syncytial virus)  Phase III  New Phase III initiated after failure of a first Phase III trial, Jan. 2017; Fast track designation granted by FDA (2016); See Remarks 
Janssen Therapeutics / Janssen Pharmaceuticals / Janssen Vaccines & Prevention / Johnson & Johnson (global presence)  TMC353121
TMC-353121; TMC 353121
 
Inhibitor  Entry and/or Fusion inhibitor (single agent)  Pneumoviridae  RSV (Respiratory Syncytial virus)  Preclinical  No further development of the RSV program (Mar. 2023); See Remarks 
  Page:
1 2

Produits: 1 - 10 (Total: 11) Page View
Next page Go to the last page
'